This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Moon, C.A.L. Articles by Doogan, D.P. Search for Related Content PubMed Articles by Moon, C.A.L. Articles by Doogan, D.P. Social Bookmarking                         What's this?

A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associated anxiety in general practice

Pool Health Centre, Station Road, Pool, Redruth, Cornwall TR15 3DU

W. Jago

Cape Cornwall Surgery, St Just, Cornwall TR19 7HH

K. Wood

Gull Rock, Treknow, Cornwall PL34 OEP

D.P. Doogan

Medical Department, Pfizer Ltd., Sandwich, Kent CT13 9NJ, UK

In this double-blind study in primary care patients, the efficacy and safety of sertraline, an antidepressant which is a selective inhibitor of serotonin re-uptake, was compared with clomipramine. Patients with DSM-III-defined major depression and with significant anxiety randomly received 50-150 mg of either sertraline (N=51) or clomipramine (N=55) once daily for 6 weeks. The mean final daily dose was 63.5 mg sertraline and 60.6 mg clomipramine. Seventy five percent of sertraline-treated and 79% of clomipramine-treated patients were maintained on the lowest dose of 50 mg once daily. The mean scores of all the rating scales (HAM-D, HAM-A, HAD, CGI) showed similar efficacy between the treatments in reducing the symptoms of depression and anxiety. Clomipramine was less well tolerated than sertraline with a greater overall incidence of side effects, or significantly greater incidence of anticholinergic side effects and significantly more patient withdrawals due to side effects; 18% in the clomipramine group compared with 4% in the sertraline group. The results indicate that sertraline is an effective agent to use in primary care patients with depression and associated symptoms of anxiety and is better tolerated than the tricyclic comparator clomipramine.

Key Words: sertraline • clomipramine • depression • anxiety • toleration

Journal of Psychopharmacology, Vol. 8, No. 3, 171-176 (1994)
DOI: 10.1177/026988119400800306


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. J. Goodnick and B. J. Goldstein Selective serotonin reuptake inhibitors in affective disorders -II. Efficacy and quality of life J Psychopharmacol, January 1, 1998; 12(4_suppl): S21 - S54. [Abstract] [PDF]